These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15266223)

  • 21. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
    Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB
    Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
    Chong PH
    Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
    Araujo R; Agustí A
    Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    McCollam PL; Foster DA; Riesmeyer JS
    Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR; Riding D
    Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
    Racine E
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM
    Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL; Fann CS; Chang CJ
    Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.
    Marsh JD
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S15-26. PubMed ID: 12434711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 37. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
    Jennings LK
    Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
    Musumeci G; Baroni M; Rossini R
    Curr Vasc Pharmacol; 2012 Jul; 10(4):443-7. PubMed ID: 22339252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
    De Luca G; Navarese E; Marino P
    Eur Heart J; 2009 Nov; 30(22):2705-13. PubMed ID: 19875386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.